Zoetis Inc. (NYSE:ZTS) has been given a $75.00 price objective by stock analysts at Cantor Fitzgerald in a report issued on Monday. The brokerage presently has a “buy” rating on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 24.51% from the stock’s previous close. Cantor Fitzgerald also issued estimates for Zoetis’ FY2017 earnings at $2.30 EPS.

Other equities research analysts have also issued reports about the company. Cowen and Company set a $70.00 price target on Zoetis and gave the stock a “buy” rating in a research note on Monday, July 17th. BMO Capital Markets downgraded Zoetis from an “outperform” rating to a “market perform” rating and upped their target price for the stock from $64.00 to $65.00 in a research report on Tuesday, June 13th. They noted that the move was a valuation call. Jefferies Group LLC upped their target price on Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, May 9th. CL King started coverage on Zoetis in a research report on Friday, May 26th. They issued a “buy” rating and a $71.00 target price for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 target price on shares of Zoetis in a research report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $64.78.

Zoetis (NYSE ZTS) traded up 1.56% during midday trading on Monday, hitting $60.66. 1,191,920 shares of the stock traded hands. The firm has a market cap of $29.67 billion, a PE ratio of 34.29 and a beta of 1.02. The company’s 50 day moving average price is $62.20 and its 200 day moving average price is $58.00. Zoetis has a 12 month low of $46.86 and a 12 month high of $63.85.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The firm’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.49 earnings per share. Equities research analysts predict that Zoetis will post $2.34 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Zoetis Inc. (NYSE:ZTS) PT Set at $75.00 by Cantor Fitzgerald” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/14/zoetis-inc-nysezts-pt-set-at-75-00-by-cantor-fitzgerald.html.

A number of hedge funds and other institutional investors have recently modified their holdings of ZTS. Macquarie Group Ltd. increased its position in shares of Zoetis by 13.2% in the fourth quarter. Macquarie Group Ltd. now owns 144,492 shares of the company’s stock worth $7,734,000 after buying an additional 16,860 shares in the last quarter. CENTRAL TRUST Co increased its position in shares of Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock worth $142,000 after buying an additional 49 shares in the last quarter. Atria Investments LLC increased its position in shares of Zoetis by 29.3% in the first quarter. Atria Investments LLC now owns 6,399 shares of the company’s stock worth $342,000 after buying an additional 1,449 shares in the last quarter. Baldwin Brothers Inc. MA acquired a new position in shares of Zoetis during the first quarter worth approximately $2,373,000. Finally, Eastern Bank increased its position in shares of Zoetis by 50.0% in the first quarter. Eastern Bank now owns 6,000 shares of the company’s stock worth $320,000 after buying an additional 2,000 shares in the last quarter. 92.70% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.